FORT MYERS, Fla. (AP) _ NeoGenomics Inc. (NEO) on Wednesday reported a loss of $22.1 million in its first quarter.

On a per-share basis, the Fort Myers, Florida-based company said it had a loss of 19 cents. Losses, adjusted for non-recurring costs and stock option expense, were 4 cents per share.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 1 cent per share.

The operator of cancer-focused testing laboratories posted revenue of $115.5 million in the period, exceeding Street forecasts. Four analysts surveyed by Zacks expected $112.6 million.

NeoGenomics expects full-year results to range from a loss of 27 cents per share to a loss of 23 cents per share.

NeoGenomics shares have dropped 12% since the beginning of the year. The stock has increased 85% in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NEO at https://www.zacks.com/ap/NEO